
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is a clinical-stage biopharmaceutical company with a strong potential for revenue growth and a focus on developing novel precision oncology therapies. With a current valuation that is attractive, the company's FDA-cleared RenovoCath medical device and its patented Trans-Arterial Micro-Perfusion therapy platform have the potential to drive significant revenue growth in 2026/2027. Positive progress in clinical drug development, along with a new CFO and consistent increase in active commercial cancer centers, further supports the potential for success in the company's phase III TIGeR-PaC trial and achieving its revenue targets. However, there are potential risks to consider, such as liquidity and regulatory approvals, that could impact the company's ability to achieve its goals.
Bears say
RenovoRx is currently undergoing a lot of changes, with a new CFO and strong progress in its clinical drug development and commercialization efforts. At first glance, the slower pace of patient enrollment in their Phase 3 trial may seem concerning, but their focus on recruiting patients with non-progressive disease after an initial induction phase could increase the likelihood of success. Additionally, their early adoption and expansion of commercial sites validate their revenue projections for 2026 and potential for significant growth in 2027. However, the loss on issuance of a financial instrument may indicate potential financial struggles for the company.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares